BYD Unveils Pictures of Exterior Design for 2023 Song Pro DM-i
On May 4th, BYD released the exterior image of the 2023 Song Pro DM-i. The new car is officially named the Song Pro DM-i Champion Edition and may be officially launched in the second quarter, with an expected price of around ¥150,000 RMB ($22,000 USD).
From the poster released by BYD, it can be seen that, in addition to upgrading the front face design with a “dragon face”, the new car also adds a brand-new “distant mountain green” exterior color.
This model adopts a large-sized front grille, which is internally supplemented with chrome-plated dotted elements, and is matched with a matte chrome trim strip that runs through both sides of the light group above the grille.
In terms of the rear end, it remains basically consistent with the current model, featuring a through-type taillight and black anti-collision guard plate.
In terms of dimensions, the new car measures 4,738 x 1,860 x 1,710 mm in length, width and height respectively, with a wheelbase of 2,712 mm.
The side profile of this model has not changed much compared to the current model but the length has increased by 88mm and the height by 10mm while the width and wheelbase remain unchanged.
In terms of power, it will be equipped with the DM-i super hybrid system, including a 1.5L naturally aspirated engine produced by BYD. The maximum power of the engine is 81 kW, and there are two specifications for the driving motor providing maximum power: 132 kW and 145 kW.
SEE ALSO: BYD’s Net Profit in 2023 Q1 Surpasses $596M, YoY Increase of 410.89%
For reference, the current model of Song Pro DM-i is equipped with two different capacities of lithium iron phosphate blade batteries, which are 8.32 kWh and 18.32 kWh respectively. The pure electric range is 51 kilometers and 110 kilometers.
It is worth mentioning that the first batch of new Song Pro DM-i Champion Edition display cars have arrived at stores nationwide. There are reports that they will officially go on sale on May 6th, but this cannot be confirmed at present.
